Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vivione Biosciences Inc. Announces the Expiration of Agreement to Acquire Trillium Diagnostics and the Establishment of a Distribution Agreement for Trillium Products

V.VBI.H

DALLAS, TX--(Marketwired - May 12, 2015) - Vivione Biosciences Inc. ("Vivione") (TSX VENTURE: VBI), announced today that it has allowed the Share Purchase Agreement ("SPA") with Trillium Diagnostics ("Trillium) dated January 26, 2015 to expire. In lieu of extending the SPA, the parties have entered into a Distribution Agreement ("Distribution Agreement") under which Vivione has the right to market, sell and use all of the biomarkers in the Trillium product line within North America and the ability to grow further into worldwide regions over the course of the three (3) year agreement. Furthermore, Vivione will have the right to obtain exclusivity within the North American market upon the attainment of defined purchase volumes.

Trillium holds licenses or patents for three biomarkers with proven diagnostic utility in infection/sepsis, including neutrophil CD64, soluble CD163, soluble CD206 and circulating cell free DNA (cfDNA). Leuko64 presently has CE IVD certification for sale in the European Union and clinical data on Leuko64 has been submitted to the FDA for its approval of IVD sales in the U.S. The Macro163 kit for measurement of soluble CD163 has been used in several large peer-reviewed clinical studies on HIV patients showing utility in prognosis of complications of chronic inflammation, in spite of good control of CD4 lymphocytes and other prognostic markers in HIV infection. Trillium also has expertise in the detection of fetomaternal hemorrhage with several IVD products, including FMH QuikQuant and FETALtrol.

Bruce H. Davis, MD, President and CEO of Trillium, commented, "We see Vivione as an important strategic partner as we continue our development of in vitro diagnostic cellular assays to fulfill the clinical need for rapid, novel and accurate diagnostics."

Kevin Kuykendall, Chairman and Chief Executive Officer of Vivione, commented, "Over the past several months we have become very familiar with Trillium's products and market and believe our ability to distribute the Trillium assays is an ideal way to leverage the speed and sensitivity of Vivione's platform technology in the testing of sepsis and severe infections. The Distribution Agreement with Trillium is a springboard for Vivione's planned entry into the clinical markets in the U.S., Canada and worldwide, and the initiation of its Sepsis Panel strategy."

Matthew Gombrich, M.D., M.S., Chief Medical Officer of Vivione commented, "Vivione's over-arching strategy is to provide infectious disease clinicians with faster and more reliable diagnostics, an improved method for antibiotic susceptibility testing, and a means to assess an individual patient's immune status." Dr. Gombrich continues, "Vivione envisions a time in the near future where the RAPID-B platform can diagnosis a blood stream infection in hours from a direct blood culture sample as opposed to days, while also providing information pertaining to targeted antibiotic therapy and immune-profiling."

About Vivione
Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system, an integrated system of hardware, software and chemical reagents that quickly and accurately identifies, quantifies and qualifies bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.

About Trillium
Trillium, located in Bangor, Maine (www.trilliumdx.com), has a focus on developing novel cellular diagnostic biomarkers on flow cytometric and immunoassay platforms for in vitro diagnostic use, as well has having expertise in laboratory hematology standardization and regulatory clearance. Trillium has leading biomarkers in the areas of infection/sepsis detection plus the monitoring and measurement of fetomaternal hemorrhage (FMH) for obstetric care.

Cautionary Statements
This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. This news release contains forward-looking information relating to the commercialization and the development of the RAPID-B system, Vivione's business and growth strategy. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this news release are made as of the date of this news release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For Additional Information Contact:
Mika Bradford
(817) 705-7221
mbradford@vivionebiosciences.com